Propranolol and etodolac

Phase 2Small molecule

SSheba Medical Center

Propranolol and etodolac is one of 51 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Ovarian CancerPhase 2

Recruiting

Competition

Competitive Landscape

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

33 2

Hycamtin

MMeitheal

Phase 3

26 3

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 5

Femara

Novartis

Phase 3

8 6

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23 7

Rubraca

Bristol-Myers Squibb

Phase 3

6 8

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 9

Neulasta

Amgen

Phase 3

2 10

Taxotere

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Metastasis

NCT03919461

Clinical

Trials by Indication[1]

Pancreatic Cancer1 trial

Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery

Unknown status·—·Phase 2·NCT03838029·210 enrolled

Metastasis1 trial

Colorectal Metastasis Prevention International Trial 2

Recruiting·—·Phase 2·NCT03919461·200 enrolled

Colorectal Cancer1 trial

β-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence

Unknown status·SSheba Medical Center·Phase 3·NCT00888797·400 enrolled

Ovarian Cancer1 trial

Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

Recruiting·TTel-Aviv Sourasky Medical Center·Phase 2·NCT06839144·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Propranolol and etodolac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Propranolol and etodolac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Propranolol and etodolac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSheba Medical Center

Propranolol and etodolac

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pancreatic Cancer1 trial

Metastasis1 trial

Colorectal Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News